Kornimate/medical-research-clean huggingface dataset:
home-based computerized cognitive rehabilitation in chronic stage stroke

Conditions: Chronic Stroke; Cognitive Impairment

Summary: this study evaluates the effectiveness of guttmann neuropersonaltrainer (gnpt), a tele-rehabilitation platform developed as a tool for the cognitive rehabilitation of chronic stroke patients. all patients will receive this treatment but in different order: half will receive gnpt and the other half will receive sham cognitive training; after a washout period of three months, crossover will occur and participants from the gnpt condition will receive sham cognitive training, while participants originally from the control intervention will receive gnpt.


Eligibility criteria:
inclusion criteria: * to be over 18 years old, * to have been diagnosed with stroke * an occurrence of the injury of 12 month period ore more (chronic stage) * cognitive impairment confirmed by pre-intervention neuropsychological assessment exclusion criteria: * diagnosis of language deficits or aphasia * motor impairment concerning upper limbs that may incapacitate them for the use of the computer * severe alteration of the visual field or perceptual problems * health status that may require further intervention or admission to a medical center during the study; * neurological or psychiatric history * substance abuse.

Keywords: computerized cognitive rehabilitation
an extension study to assess the safety, tolerability and efficacy of abt-slv187 in subjects with advanced parkinson's disease and persistent motor-complications despite optimized treatment with available anti-parkinsonian medications

Conditions: Advanced Parkinson's Disease

Summary: this is an extension study to evaluate the long-term safety and tolerability of abt-slv187 in subjects with advanced parkinson's disease.


Eligibility criteria:
inclusion criteria: 1. subjects completing 12 weeks treatment in study m12-921 who would benefit from long-term treatment from abt-slv187. alternatively, subjects who (i) participated in the phase 2 study m12-925 (ii) would, in the opinion of the investigator, benefit from abt-slv187 treatment in the study m12-923, (iii) did not discontinue the m12-925 study due to safety reason, and (iv) meet all entry requirements. lastly, subjects who completed another abt-slv187 study (e.g., study m12-927) in south korea. 2. the subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen). 3. the subject must be willing to continue on treatment. exclusion criteria: 1. subject is enrolled in another clinical trial. 2. psychiatric, neurological or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study. 3. medical, laboratory, or surgical issues deemed by the investigator to be clinically significant and in the opinion of the pi, would be a contraindication to continued levodopa therapy. 4. uncooperative attitude or reasonable likelihood for non-compliance with the protocol. 5. subject has current significant suicidal ideation as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the columbia-suicide severity rating scale completed at the week 12 visit of study m12-921 or at the baseline visit of the current study for m12-925 or m12-927 study subjects. 6. consideration by the investigator, for any reason, that the subject is an unsuitable candidate to continue to receive abt-slv187.

Keywords: safety tolerability efficacy levodopa-carbidopa intestinal gel levodopa carbidopa advanced parkinson's disease
energy regulation and nutritional status of children: a satiation study

Conditions: Underweight; Stunting; Healthy

Summary: this is study among children attending child welfare clinics in greater accra region of ghana. the investigators want to find out if moderately malnourished children regulate the food energy intake similarly to healthy children, using an established method to assess energy compensation.

malnutrition originates from a complex interplay between genes and environment, manifesting in changes to hormones, metabolism, and behaviour. energy regulation which determines food intake or avoidance plays a significant role in the cause, prevention and treatment of malnutrition. there is however limited knowledge of how energy regulation develops in children and its effect on their nutritional status in the context of undernutrition in children. a good understanding of energy regulation in children is therefore essential in designing interventions for tackling infant malnutrition. a standardised energy compensation study will be undertaken in 60 children- 20 moderately malnourished, 20 stunted and 20 healthy. at two visits at least a week apart, the children will be given one of two similar tasting drinks in random order, one with very few calories and another with extra, without them knowing which is which. after 30 minutes they will eat as much as they want of a standardized lunch. all foods and drinks offered will be weighed before and after, to calculate the amount of energy eaten in total after the low energy drink, compared to the high energy drink.

Eligibility criteria:
inclusion criteria: * moderately malnourished (whz between -3 and -2 z-scores) or stunted (haz\ -2sd and haz \>-2sd) children age 12-36 months. * children should be attending child welfare clinics at the selected communities. * the children should be accompanied by a main caregiver who is actively involved in cooking for and/or feeding the child. * children who are able to fast for at least 2 hours prior to the experiment. exclusion criteria: * children with congenital disorders, disabilities and diseases requiring specialised care and hospitalisation. * children with severe malnutrition with complications that required inpatient care. * tube-fed children. * children who are both stunted and moderately malnourished
workplace based physiotherapy of elderly-care workers with non-specific neck pain.

Conditions: Neck Pain

Summary: the overall objective of this study is to determine the efficacy of a physical therapy intervention based on manual therapy, therapeutic exercise and application of electrotherapy in healthcare workers with non-specific neck pain.

the subjects included in the sample will be evaluated according to the aforementioned parameters by researchers trained and assigned for this purpose. the data collection of the different variables will be performed before and after the completion of the program designed for the study. the physiotherapy intervention for the experimental group will have a duration of 10 sessions, twice a week.

Eligibility criteria:
iinclusion criteria: * age range between 18-60 years. * cervical pain of non-specific origin or cervicalgia type i and ii according to the quebec - task force on spinal disorders. * be willing to participate in the study and sign the informed consent form. * have at least one year of seniority in the company exercising the current professional activity within the team of socio-health personnel. exclusion criteria: * cervicalgia with neurological involvement or caused by pathologies such as: inflammatory disease, neurological disease, rheumatic disease, severe osteoporosis, fracture, dislocation, vertebro-basilar insufficiency, neoplasia or infection. * spine surgery. * present metallic implants at the spinal column level. * have received physiotherapy or alternative treatment in the last 6 months before starting the study. * to present any type of inconvenience to the application of electrotherapy (score ≥45 points in eapp).

Keywords: non specific pain physiotherapy manual therapy electrical stimulation therapy therapeutic exercise
a research study to look into the long-term effect on weight loss of cagrisema in people with obesity

Conditions: Obesity

Summary: this study will look at how well cagrisema helps people with obesity lose weight compared to a "dummy medicine". cagrisema is a new medicine developed by novo nordisk. cagrisema cannot yet be prescribed by doctors. the study has two parts: first part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. in the main phase participants will either get cagrisema or "dummy medicine". which treatment participants get is decided by chance and is not known by participants or the study doctor. in the extension phase participants will get either cagrisema or slowly reduce participants dose of cagrisema if participants had cagrisema in the main phase. which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. if participants had "dummy medicine" in the main phase, participants will get cagrisema in the extension phase. like all medicines, the study medicine may have side effects.


Eligibility criteria:
inclusion criteria: * male or female. * age above or equal to 18 years at the time of signing informed consent. * body mass index (bmi) greater than or equal to (\>=) 35.0 kilograms per meter square (kg/m\^2). exclusion criteria: * glycated haemoglobin (hba1c) \>= 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * history of type 1 or type 2 diabetes.
efficacy, safety and satisfaction of the new pen needle 33 gauge x 4 mm.

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: during the last years, even more little needles are used for the injection of sub cutaneous insulin, for the diabetes therapy. the aim of this study is to evaluate the non inferiority of a new needle, smaller than another needle, in terms of hematic levels od fructosamine, an indicator of glycemic control.


Eligibility criteria:
inclusion criteria: * patients with type 1 or type 2 diabetes * both males and females * age \>=18 anni * insulin treatment from at least 6 months * signed informed consent exclusion criteria: * pregnancy * incapacity for filling in the questionnaires * every illness or condition that, according to the investigator, could interfere with the study

Keywords: diabetes insulin therapy needle
comparison of frozen-thawed embryo transfers and fresh embryo transfers with whole chromosome analysis using next generation sequencing

Conditions: Infertility

Summary: the investigators propose to perform a clinical randomized trial to evaluate the effect of a frozen-thawed embryo transfer and a fresh embryo transfer on pregnancy and implantation rates; with the added benefit of a blastocyst biopsy and whole chromosome analysis by next generation sequencing (ngs).

1. fresh group: all embryos will be hatched on day 3. patients will have hatching blastocysts (\*) biopsied on day 5, analyzed by ngs, and will have one or two euploid embryo transferred on day 6, in the am. if more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (\*). any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle. 2. frozen group: all embryos will be hatched on day 3. patients will have hatching blastocysts (\*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by ngs, and will have one or two euploid embryo(s) thawed and transferred on a fet cycle, before noon. if more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (\*). (\*) hatching blastocysts as described by gardner and schoolcraft (1999):

Eligibility criteria:
inclusion criteria (pre-stimulation): * age up to 42 years exclusion criteria (pre-stimulation): * mesa and tese patients * at least one partner carrier of a chromosomal abnormality * egg donor cycle (sperm donor is acceptable) * gender selection cycles * thaw cycles * any patient who cannot have a fresh embryo transfer * fsh above 12 or amh less than 1

Keywords: infertility next generation sequencing
effect of nurse-led education and tele-interventions on reducing surgical site infections in patients after coronary artery bypass surgery: a clinical trial

Conditions: Surgical Site Infection; Coronary Artery Bypass Grafting (CABG)

Summary: the goal of this clinical trial is to determine if nurse-led education and tele-interventions can reduce the incidence of surgical wound infections in patients after coronary artery bypass surgery. the main questions it aims to answer are: * can nurse-led education reduce the rate of surgical wound infections after coronary artery bypass surgery? * does the addition of tele-interventions further decrease the incidence of these infections compared to standard care? researchers will compare three groups: * group a: standard postoperative care * group b: nurse-led patient education * group c: nurse-led patient education plus tele-interventions participants will: * receive standard care, nurse-led education, or nurse-led education with tele-interventions * having regular follow-up as per group assignment * monitor and report infection during the study period


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients who have undergone cabg with median sternotomy * proficiency in reading and writing in greek * patients who provide written informed consent for participation in the study * patients who have access to a mobile phone and know how to use it * patients without difficulties in vision, speech, or hearing * patients at intermediate or high risk for developing surgical site infections, based on their scores in the risk stratification models described below exclusion criteria: * history of psychiatric illness, recent history of alcohol and/or substance abuse, dementia, and alzheimer's disease * presence of an active infection within 2 weeks prior to the surgical procedure * preoperative hospitalization \> 2 days * concurrent surgery on the aorta or heart valves * urgent or emergency nature of the surgical procedure * re-sternotomy aimed at surgical re-exploration of bleeding or implementation of cardiopulmonary resuscitation (cpr) in cases of cardiac arrest * patients in whom the sternum has not been closed after the completion of the surgical procedure and who are transferred to the cardiothoracic unit without sternum closure * active endocarditis * life expectancy \< 6 months * lack of a smartphone
linking epigenomics with prescription opioid abuse and high impact musculoskeletal pain

Conditions: Pain, Chronic; Prescription Drug Abuse (Not Dependent)

Summary: genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.

over 19 million adults suffer with chronic pain, which frequently limits life or work activities. many of these patients are chronic prescription opioid consumers and may be at risk for opioid use disorder. genetic variability of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain (hicmp), opioid efficacy, and vulnerability to opioid abuse. there is a paucity of research on the epigenetic profile of patients with hicmp and of those who fall in the spectrum between opioid addicted and opioid naive. exploring the role of epigenomics in hicmp and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce development. the long-term goal is to create a profile of genetic and psychosocial risk factors for identifying patients susceptible to hicmp and opioid abuse. the objective of this pilot study is to gather preliminary data on the association of epigenetic modification of genes with hicmp and prescription opioid abuse.the study team propose to compare comt and oprm1 dna methylation patterns in patients with hicmp (group 1) to those without hicmp (group 2).the investigators will also correlate oprm1 dna methylation patterns with the likelihood of misuse and abuse in chronic opioid consumers. it is hypothesized: (1) the promoter region of the comt and oprm1 genes will be hypo- and hyper-methylated, respectively, in group 1 compared to group 2; and (2) the oprm1 gene in patients at high risk for opioid misuse and abuse will be hyper-methylated.

Eligibility criteria:
inclusion criteria: * patients age ≥18 years with chronic musculoskeletal pain (pain present for 3 or more months) treated with prescription opioids on most days in the past 3 months. exclusion criteria: * patients who are non-english speaking, * patients who are incarcerated * patients who are unable to provide consent will be excluded.
remote tracking of epilepsy patients

Conditions: Epilepsy

Summary: the investigators propose a novel method for tracking the seizure frequency, side effect burden, and medication compliance for patients with epilepsy. the investigators intend to utilize a table-top device currently for tracking other chronic disease to collect remote data from epilepsy patients. the hypothesis is that the use of this device will lead to better longterm treatment outcomes than the standard outpatient mechanism of following patients longitudinally.


Eligibility criteria:
inclusion criteria: * eligible participants must have a definitive diagnosis of epilepsy for at least 6 months, based on the clinical judgement of the investigators. epilepsy is defined by two or more unprovoked seizures. clinical history, electroencephalography, and imaging data are all instrumental in rendering a formal decision. the seizure type, frequency, or severity are not criteria for exclusion, although this information will be recorded. patient can range in age from birth to 65 years old; in cases of child participants, the parents are responsible for data reporting. * patients must have a seizure frequency of at least two seizures in a 6 month period of time. * patients must be on at least one anti-epileptic medication. * patients and/or legal guardian must be able to report seizure frequency with either a paper or electronic diary. * patients and/or legal guardians must be able to read and understand either english or spanish. * patients and/or legal guardians must be able to complete questionnaires and provide informed consent to this study. exclusion criteria: * exclusion criteria include: a diagnosis of psychogenic nonepileptic seizures; severe depression, anxiety, or psychosis * recent problem with substance abuse.

Keywords: epilepsy tracking electronic diary
measuring the influence of maxillary obturator prosthesis on facial morphology in patient with unilateral maxillary defects using stereophotogrammetry

Conditions: Facial Asymmetry

Summary: functional rehabilitation and quality of life after maxillofacial surgery have been emphasized in recent years. it depends mainly on outcomes of maxillofacial reconstruction and rehabilitation involving functions, esthetics, psychology acceptance and resocialization. tooth loss, alveolar and maxillary bone resorption or changes of the hard palate cause facial asymmetry in patient with maxillofacial surgery. the facial soft tissue over the defect become recessed as a result of loss of lip and buccal support which lead to decrease the quality of life and psychological disorders. prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. the purpose of this study is to investigate the influence of maxillary obturator on facial morphology in patient with unilateral maxillary defect by using 3 dimensional digital stereophotogrammetry compared to the intact side of the same patient


Eligibility criteria:
inclusion criteria: * adult patient of both sexes, 6 months after partial maxillectomy with good periodontal condition of remaining tooth especially abutment tooth. exclusion criteria: * patient with history of radiotherapy, bad oral hygiene patient with tumor recurrence, patient with mental instability, patient with systemic disorders like uncontrolled diabetes, compromised heart function
assessing the long-term safety and to explore the long-term efficacy of zonisamide as monotherapy in newly diagnosed partial seizures

Conditions: Epilepsy

Summary: the purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.


Eligibility criteria:
inclusion criteria: 1. subject has completed study e2090-e044-310. 2. subject is able and willing to give written informed consent. 3. female subjects without childbearing potential (two years post-menopausal, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. female subjects of childbearing potential must be non-pregnant, non-lactating and abide by one of the following medically acceptable contraceptive measures: oral contraceptive pill, contraceptive injections, implants or patches, intrauterine device in place for at least three months, vasectomised partner or abstinence throughout the study and for one month after discontinuation of study medication. when the contraceptive pill is used, this should contain no less than 50 μg oestrogen. 4. the subject is able and willing to follow the investigational study procedures, maintain a seizure diary and report adverse events. exclusion criteria: 1. subject has a history of a significant or currently uncontrolled disease that will contraindicate the use of the study drugs or interfere with the conduct of this study and/or the assessment of safety and efficacy of the study drugs. 2. subject has a body weight \<40 kg. 3. subject has a newly occurring progressive malignancy during study e2090-e044-310 (excluding a history of non-metastasized and adequately treated cutaneous squamous cell carcinoma). 4. subject has developed a psychiatric illness or mood disorder requiring electro-convulsive or drug therapy within the previous 6 months and is considered uncontrolled; history of suicide attempt, alcohol or drug abuse, chronic treatment with benzodiazepines or barbiturates. 5. subject is currently taking carbonic anhydrase inhibitors. 6. subject developed pancreatitis, nephrolithiasis or hypercalcuria, clinically significant laboratory abnormalities, stroke or uncontrolled hypertension during study e2090-e044-310. 7. subject is currently taking monoamine oxidase inhibitors (maois) or any other excluded medications (see protocol section 9.9.3). 8. subject has a history of allergy to carbamazepine or to zonisamide or to any of their ingredients or to sulphonamides. 9. subject has developed a bone marrow depression, low platelet count or other blood dyscrasias.

Keywords: epilepsy monotherapy